Raloxifene
chemical compound
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Common side effects include hot flashes, leg cramps, swelling, and joint pain. Severe side effects may include blood clots and stroke. Use during pregnancy may harm the baby. The medication may worsen menstrual symptoms. Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus.
The public source identifies “Raloxifene” as chemical compound. This brief keeps that definition visible, then builds a research path around Raloxifene, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Raloxifene”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Dec 22, 2025. The linked authority identifier is Q425223. The Library of Congress control number is sh00009274. None of the 1 selected statements returned an explicit reference.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Raloxifene”, its source revision and the description used here.
- Expand the search: follow Raloxifene primary sources, Raloxifene archive and Raloxifene research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Raloxifene”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Raloxifene” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.